Published in Osteoporos Int on July 27, 2017
Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med (2007) 7.60
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) (2010) 4.65
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (2015) 4.58
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med (1998) 4.38
Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol (2007) 4.11
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab (2007) 4.01
Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med (2007) 3.50
Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int (2016) 3.30
Fracture incidence after 3 years of aromatase inhibitor therapy. Ann Oncol (2014) 3.18
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med (2005) 2.98
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology (2004) 2.44
Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med (2011) 2.34
Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int (2006) 2.33
Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab (2005) 2.23
Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med (2007) 2.17
Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis. J Thromb Haemost (2015) 2.14
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol (2010) 1.99
Hyponatremia-induced osteoporosis. J Bone Miner Res (2010) 1.95
Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation. JAMA (2017) 1.95
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res (2000) 1.80
Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum (1999) 1.58
Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int (2015) 1.52
Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol (2014) 1.46
Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med (1990) 1.40
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med (2017) 1.39
Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology (2006) 1.36
Best practice guidelines for the management of women with epilepsy. Epilepsia (2005) 1.33
Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data. Osteoporos Int (2017) 1.26
Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception (2006) 1.21
A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother (2010) 1.20
Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int (2010) 1.17
Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol (1993) 1.17
Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol (2010) 1.16
Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception (2008) 1.06
Loop diuretic use and fracture in postmenopausal women: findings from the Women's Health Initiative. Arch Intern Med (2009) 1.05
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab (2015) 1.03
Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res (2005) 1.03
Prolonged heparin therapy in pregnancy causes bone demineralization. Br J Obstet Gynaecol (1983) 1.01
Risk factors for hip fracture in men. Hip Fracture Study Group. Am J Epidemiol (1997) 1.01
Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat (2009) 0.98
Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol (2013) 0.97
Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses. J Endocrinol Invest (1988) 0.94
Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors. J Neurol Sci (2013) 0.92
Fracture risk in patients treated with loop diuretics. J Intern Med (2006) 0.92
Fibroid growth and medical options for treatment. Fertil Steril (2014) 0.91
Diuretic Use and Risk of Vertebral Fracture in Women. Am J Med (2016) 0.90
A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol (1994) 0.90
Effects of three years of low-dose thiazides on mineral metabolism in healthy elderly persons. Osteoporos Int (2008) 0.88
Use of selective serotonin reuptake inhibitors and bone mass in adolescents: An NHANES study. Bone (2015) 0.88
Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. J Clin Endocrinol Metab (2015) 0.87
Glucocorticoid-Induced Osteoporosis. Adv Exp Med Biol (2015) 0.85
Effects of third-generation aromatase inhibitors on bone. Eur J Cancer (2006) 0.85
Bone mineral density and body composition in girls with idiopathic central precocious puberty before and after treatment with a gonadotropin-releasing hormone agonist. Clinics (Sao Paulo) (2012) 0.85
Glucocorticoid-induced Osteoporosis. Rheum Dis Clin North Am (2015) 0.84
The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty. Clin Endocrinol (Oxf) (2012) 0.84
Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J Bone Miner Res (2015) 0.82
The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. Osteoporos Int (2016) 0.81
Antiresorptive therapy in the management of cancer treatment-induced bone loss. Curr Osteoporos Rep (2015) 0.81
Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res (2014) 0.81
Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond Engl) (2015) 0.80
Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. BMC Cancer (2015) 0.79
Serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor use and risk of fractures: a new-user cohort study among US adults aged 50 years and older. CNS Drugs (2015) 0.78
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. Support Care Cancer (2015) 0.78
Safety of medical treatments for endometriosis. Expert Opin Drug Saf (2015) 0.78
The updated Cochrane review 2014 on GnRH agonist trigger: an indispensable piece of information for the clinician. Reprod Biomed Online (2015) 0.78
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. J Am Coll Cardiol (2016) 0.77
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. Breast Cancer Res Treat (2015) 0.77
Low-dose add-back therapy during postoperative GnRH agonist treatment. Taiwan J Obstet Gynecol (2016) 0.77
Hyponatremia and fractures: should hyponatremia be further studied as a potential biochemical risk factor to be included in FRAX algorithms? Osteoporos Int (2017) 0.77
Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy. Osteoporos Int (2014) 0.77
Possible methods for the prevention of bone loss in persons with epilepsy. Expert Rev Neurother (2009) 0.76
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol (2017) 0.76
Bone health management in men undergoing ADT: examining enablers and barriers to care. Osteoporos Int (2014) 0.76
Basic understanding of gonadotropin-releasing hormone-agonist triggering. Fertil Steril (2015) 0.76
Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol (2016) 0.76
Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial. Osteoporos Int (2015) 0.76
SSRI use and risk of fractures among perimenopausal women without mental disorders. Inj Prev (2015) 0.76
Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am J Obstet Gynecol (2002) 0.76
Overview of elagolix for the treatment of endometriosis. Expert Opin Drug Metab Toxicol (2016) 0.76
Association of Proton Pump Inhibitor Use with Recurrent Falls and Risk of Fractures in Older Women: A Study of Medication Use in Older Fallers. J Nutr Health Aging (2016) 0.76
Use of antipsychotics increases the risk of fracture: a systematic review and meta-analysis. Osteoporos Int (2017) 0.76
Advances in pharmacotherapy for treating endometriosis. Expert Opin Pharmacother (2015) 0.75
Use of proton pump inhibitors and mortality after hip fracture in a nationwide study. Osteoporos Int (2017) 0.75
Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study. Prostate Cancer Prostatic Dis (2014) 0.75
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol (2017) 0.75